Centessa Pharmaceuticals (uk) Limited
Clinical trials sponsored by Centessa Pharmaceuticals (uk) Limited, explained in plain language.
-
New brain protein mimic could help people stay awake
Disease control Recruiting nowThis study is testing a new drug called ORX750 in people with narcolepsy or idiopathic hypersomnia—conditions that cause severe daytime sleepiness. The drug is designed to act like a natural brain protein (orexin) that helps keep people awake. Researchers will check if ORX750 is …
Phase: PHASE2 • Sponsor: Centessa Pharmaceuticals (UK) Limited • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
Extended trial tests sleep disorder drug's long-term effects
Disease control Recruiting nowThis study continues testing the ORX750 medication for people with narcolepsy and idiopathic hypersomnia who completed an earlier trial. It aims to understand the long-term safety and effectiveness of the drug when taken over an extended period. The research will monitor side eff…
Phase: PHASE2 • Sponsor: Centessa Pharmaceuticals (UK) Limited • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New drug tested to fight daytime sleepiness
Symptom relief Recruiting nowThis is an early-stage study to test the safety of a new drug called ORX142 for people who struggle with excessive daytime sleepiness. Researchers will give the drug to healthy adults, including some who are sleep-deprived, to see how their bodies handle it and if it helps them s…
Phase: PHASE1 • Sponsor: Centessa Pharmaceuticals (UK) Limited • Aim: Symptom relief
Last updated Mar 30, 2026 14:33 UTC
-
New wakefulness drug begins first human tests
Knowledge-focused Recruiting nowThis is an early-stage study to check the safety of a new oral drug called ORX489 in healthy adults. Researchers will give single and multiple doses to see how the body handles the drug and if it helps people stay awake. The main goal is to understand the drug's side effects and …
Phase: PHASE1 • Sponsor: Centessa Pharmaceuticals (UK) Limited • Aim: Knowledge-focused
Last updated Apr 02, 2026 14:56 UTC